» Articles » PMID: 17020766

Crystal Structure of the Human Prostacyclin Synthase

Overview
Journal J Mol Biol
Publisher Elsevier
Date 2006 Oct 6
PMID 17020766
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Prostacyclin synthase (PGIS) catalyzes an isomerization of prostaglandin H(2) to prostacyclin, a potent mediator of vasodilation and anti-platelet aggregation. Here, we report the crystal structure of human PGIS at 2.15 A resolution, which represents the first three-dimensional structure of a class III cytochrome P450. While notable sequence divergence has been recognized between PGIS and other P450s, PGIS exhibits the typical triangular prism-shaped P450 fold with only moderate structural differences. The conserved acid-alcohol pair in the I helix of P450s is replaced by residues G286 and N287 in PGIS, but the distinctive disruption of the I helix and the presence of a nearby water channel remain conserved. The side-chain of N287 appears to be positioned to facilitate the endoperoxide bond cleavage, suggesting a functional conservation of this residue in O-O bond cleavage. A combination of bent I helix and tilted B' helix creates a channel extending from the heme distal pocket, which seemingly allows binding of various ligands; however, residue W282, placed in this channel at a distance of 8.4 A from the iron with its indole side-chain lying parallel with the porphyrin plane, may serve as a threshold to exclude most ligands from binding. Additionally, a long "meander" region protruding from the protein surface may impede electron transfer. Although the primary sequence of the PGIS cysteine ligand loop diverges significantly from the consensus, conserved tertiary structure and hydrogen bonding pattern are observed for this region. The substrate-binding model was constructed and the structural basis for prostacyclin biosynthesis is discussed.

Citing Articles

Non-Canonical Cytochrome P450 Enzymes in Nature.

Nguy A, Ireland K, Kayrouz C, Caceres J, Greene B, Davis K bioRxiv. 2025; .

PMID: 39763895 PMC: 11703216. DOI: 10.1101/2024.12.22.630014.


In silico design and in vitro assessment of anti-Helicobacter pylori compounds as potential small-molecule arginase inhibitors.

Thereza Fiori-Duarte A, Guarnieri J, Rodrigues Pereira de Oliveira Borlot J, Lancellotti M, Rodrigues R, Kitagawa R Mol Divers. 2022; 26(6):3365-3378.

PMID: 34997872 DOI: 10.1007/s11030-021-10371-8.


A combined computational strategy of sequence and structural analysis predicts the existence of a functional eicosanoid pathway in Drosophila melanogaster.

Scarpati M, Qi Y, Govind S, Singh S PLoS One. 2019; 14(2):e0211897.

PMID: 30753230 PMC: 6372189. DOI: 10.1371/journal.pone.0211897.


Human cytochrome P450 enzymes 5-51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition - toxic effects and benefits.

Rendic S, Guengerich F Drug Metab Rev. 2019; 50(3):256-342.

PMID: 30717606 PMC: 6421578. DOI: 10.1080/03602532.2018.1483401.


Prostaglandin terminal synthases as novel therapeutic targets.

Hara S Proc Jpn Acad Ser B Phys Biol Sci. 2017; 93(9):703-723.

PMID: 29129850 PMC: 5743848. DOI: 10.2183/pjab.93.044.


References
1.
Sevrioukova I, Li H, Zhang H, Peterson J, Poulos T . Structure of a cytochrome P450-redox partner electron-transfer complex. Proc Natl Acad Sci U S A. 1999; 96(5):1863-8. PMC: 26702. DOI: 10.1073/pnas.96.5.1863. View

2.
Terwilliger T, Berendzen J . Automated MAD and MIR structure solution. Acta Crystallogr D Biol Crystallogr. 1999; 55(Pt 4):849-61. PMC: 2746121. DOI: 10.1107/s0907444999000839. View

3.
Terwilliger T . Maximum-likelihood density modification. Acta Crystallogr D Biol Crystallogr. 2000; 56(Pt 8):965-72. PMC: 2792768. DOI: 10.1107/s0907444900005072. View

4.
Williams P, Cosme J, Sridhar V, Johnson E, McRee D . Microsomal cytochrome P450 2C5: comparison to microbial P450s and unique features. J Inorg Biochem. 2000; 81(3):183-90. DOI: 10.1016/s0162-0134(00)00102-1. View

5.
Podust L, Poulos T, Waterman M . Crystal structure of cytochrome P450 14alpha -sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors. Proc Natl Acad Sci U S A. 2001; 98(6):3068-73. PMC: 30608. DOI: 10.1073/pnas.061562898. View